Novo Nordisk’s Key Drug Trial Misses Primary Endpoint amid Shareholder Litigation Risks Over Weight-Loss Drugs

Market Focus

Jul 31

On July 31, Novo-Nordisk A/S unveiled top-line Phase 3 results from its ZEUS cardiovascular trial today. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, evidenced by anticipated reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP), these biological effects did not translate into a lower risk of major adverse cardiovascular events (MACE) versus placebo among patients living with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammation (hazard ratio, 0.99; 95% confidence interval, 0.88–1.11).

Novo-Nordisk A/S fell over 10% in pre-market trading.

Meanwhile, a US court recently ruled that Novo Nordisk must face certain shareholder allegations related to statements made about its next-generation weight-loss drug CagriSema's clinical trials, marking a material escalation of litigation risk. The lawsuit stems from CagriSema's failure to achieve the company's projected 25% average weight loss target in Phase III trials, with multiple shareholders alleging disclosure violations.

Novo Nordisk responded that the allegations are baseless and pledged to mount a full defense.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1147499462"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147499462\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147499462?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147499462","market":"us","top_or_hot":-1,"title":"Novo Nordisk’s Key Drug Trial Misses Primary Endpoint amid Shareholder Litigation Risks Over Weight-Loss Drugs","media":"Market Focus","content":"<html><head></head><body><p style=\"text-align: left;\">On July 31, <a href=\"https://laohu8.com/S/NVO\">Novo-Nordisk A/S</a> unveiled top-line Phase 3 results from its ZEUS cardiovascular trial today. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, evidenced by anticipated reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP), these biological effects did not translate into a lower risk of major adverse cardiovascular events (MACE) versus placebo among patients living with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammation (hazard ratio, 0.99; 95% confidence interval, 0.88–1.11).</p><p style=\"text-align: left;\"><a href=\"https://laohu8.com/S/NVO\">Novo-Nordisk A/S</a> fell over 10% in pre-market trading. </p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3a2531caf9f1f04883e3b3cb0cbcffca\" data-align=\"center\" tg-width=\"1248\" tg-height=\"642\"/><span></span></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0d9edfa37326b244a412fcbd3ce59ee8\" data-align=\"center\" tg-width=\"701\" tg-height=\"753\"/><span></span></p><p style=\"text-align: left;\">Meanwhile, a US court recently ruled that Novo Nordisk must face certain shareholder allegations related to statements made about its next-generation weight-loss drug CagriSema&#39;s clinical trials, marking a material escalation of litigation risk. The lawsuit stems from CagriSema&#39;s failure to achieve the company&#39;s projected 25% average weight loss target in Phase III trials, with multiple shareholders alleging disclosure violations.</p><p style=\"text-align: left;\">Novo Nordisk responded that the allegations are baseless and pledged to mount a full defense.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p><p style=\"text-align: left;\"></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk’s Key Drug Trial Misses Primary Endpoint amid Shareholder Litigation Risks Over Weight-Loss Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk’s Key Drug Trial Misses Primary Endpoint amid Shareholder Litigation Risks Over Weight-Loss Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">On July 31, <a href=\"https://laohu8.com/S/NVO\">Novo-Nordisk A/S</a> unveiled top-line Phase 3 results from its ZEUS cardiovascular trial today. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, evidenced by anticipated reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP), these biological effects did not translate into a lower risk of major adverse cardiovascular events (MACE) versus placebo among patients living with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammation (hazard ratio, 0.99; 95% confidence interval, 0.88–1.11).</p><p style=\"text-align: left;\"><a href=\"https://laohu8.com/S/NVO\">Novo-Nordisk A/S</a> fell over 10% in pre-market trading. </p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3a2531caf9f1f04883e3b3cb0cbcffca\" data-align=\"center\" tg-width=\"1248\" tg-height=\"642\"/><span></span></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0d9edfa37326b244a412fcbd3ce59ee8\" data-align=\"center\" tg-width=\"701\" tg-height=\"753\"/><span></span></p><p style=\"text-align: left;\">Meanwhile, a US court recently ruled that Novo Nordisk must face certain shareholder allegations related to statements made about its next-generation weight-loss drug CagriSema&#39;s clinical trials, marking a material escalation of litigation risk. The lawsuit stems from CagriSema&#39;s failure to achieve the company&#39;s projected 25% average weight loss target in Phase III trials, with multiple shareholders alleging disclosure violations.</p><p style=\"text-align: left;\">Novo Nordisk responded that the allegations are baseless and pledged to mount a full defense.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p><p style=\"text-align: left;\"></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1147499462","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147499462","pubTimestamp":1785497029,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, Novo-Nordisk A/S fell 10.87% in pre-market trading, trading around $45.84/share, with turnover of approximately $10.12 million.On the news front, a US court recently ruled that Novo...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"NVO盘前交易下跌10%，法院受理CagriSema股东诉讼诉讼风险升级","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/59ae4f9b4738d8cfd82789a0cb2d0516","symbols_score_info":{"NVO":1},"content_text":"On July 31, Novo-Nordisk A/S unveiled top-line Phase 3 results from its ZEUS cardiovascular trial today. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, evidenced by anticipated reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP), these biological effects did not translate into a lower risk of major adverse cardiovascular events (MACE) versus placebo among patients living with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammation (hazard ratio, 0.99; 95% confidence interval, 0.88–1.11).Novo-Nordisk A/S fell over 10% in pre-market trading. Meanwhile, a US court recently ruled that Novo Nordisk must face certain shareholder allegations related to statements made about its next-generation weight-loss drug CagriSema's clinical trials, marking a material escalation of litigation risk. The lawsuit stems from CagriSema's failure to achieve the company's projected 25% average weight loss target in Phase III trials, with multiple shareholders alleging disclosure violations.Novo Nordisk responded that the allegations are baseless and pledged to mount a full defense.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}